These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12681968)

  • 1. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
    Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
    [No Abstract]   [Full Text] [Related]  

  • 4. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib.
    Drechsler M; Hildebrandt B; Kündgen A; Germing U; Royer-Pokora B
    Ann Hematol; 2007 May; 86(5):353-4. PubMed ID: 17211520
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
    Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein.
    Sjöblom T; Boureux A; Rönnstrand L; Heldin CH; Ghysdael J; Ostman A
    Oncogene; 1999 Nov; 18(50):7055-62. PubMed ID: 10597306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
    Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
    Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tel/PDGFRbeta inhibits self-renewal and directs myelomonocytic differentiation of ES cells.
    Dobbin E; Corrigan PM; Walsh CP; Welham MJ; Freeburn RW; Wheadon H
    Leuk Res; 2008 Oct; 32(10):1554-64. PubMed ID: 18355917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
    Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
    Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta).
    Bourgeade MF; Défachelles AS; Cayre YE
    Blood; 1998 May; 91(9):3333-9. PubMed ID: 9558390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
    Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
    J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
    Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation.
    Funakoshi-Tago M; Tago K; Nishizawa C; Takahashi K; Mashino T; Iwata S; Inoue H; Sonoda Y; Kasahara T
    Biochem Pharmacol; 2008 Dec; 76(12):1681-93. PubMed ID: 18848530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.